Drug‐induced psoriasiform alopecia associated with interleukin‐17 inhibitor therapy
| Autor: | Timothy L. Tan, Pedram Yazdan, Lauren Taglia |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Drug
Pathology medicine.medical_specialty Histology media_common.quotation_subject Dermatology Pathology and Forensic Medicine 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Atrophy Psoriasis Biopsy Medicine Psoriasiform Dermatitis media_common integumentary system medicine.diagnostic_test business.industry medicine.disease Ixekizumab medicine.anatomical_structure 030220 oncology & carcinogenesis Scalp Interleukin 17 business |
| Zdroj: | Journal of Cutaneous Pathology. 48:771-774 |
| ISSN: | 1600-0560 0303-6987 |
| Popis: | Drug-induced psoriasiform alopecia is an increasingly recognized form of alopecia mostly reported in association with TNF-alpha inhibitors. However, drug-induced psoriasiform alopecia in association with IL-17A inhibitors has not been described. We present a 62-year-old woman with severe psoriasis who developed new psoriatic plaques on the scalp with alopecia after initiating ixekizumab (anti-IL-17A). Scalp biopsy specimens revealed a non-cicatricial alopecia with increased telogen/catagen follicles, atrophy of the sebaceous glands, peribulbar and perifollicular inflammation with frequent lymphocytes, plasma cells, eosinophils, psoriasiform dermatitis, and lack of intra-corneal or intra-epidermal neutrophils. Overall, the clinical and histopathologic findings were most compatible with a drug-induced psoriasiform alopecia in association with IL-17A inhibitor therapy. Our case shows that drug-induced psoriasiform alopecia can paradoxically occur in patients on IL-17A inhibitor therapy and contributes to the growing list of cutaneous eruptions associated with biologic agents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|